| Authors suggest that SET/TAF-Ialpha might be a tumor suppressing factor regulated by miR-21-5p in lung adenocarcinoma. | lung, |
| PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. | prostate, |
| SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. | lymphoma,leukemia, |
| Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma. | sarcoma, |
| SET overexpression is a frequent event in metastatic colorectal cancer that plays a potential oncogenic role associated with worse outcome and resistance to oxaliplatin. | colorectal, |
| Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. | lung, |
| Our findings suggested the oncogenic role of SET and the adverse prognostic value of SET overexpression in hepatocellular carcinoma (HCC). This alteration defines a subgroup of HCC patients who could benefit from SET antagonists, such as EMQA. | liver, |
| SEToverexpression promotes morphological and oncogenic cell transformation of an oral keratinocyte cell. | oral |
| Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. | None |
| Purification, crystallization and preliminary X-ray diffraction analysis of human oncoprotein SET/TAF-1beta. | None |
| Prothymosin alpha associates with the oncoprotein SET and is involved in chromatin decondensation. | None |
| The oncoprotein I-2PP2A/SET negatively regulates the MEK/ERK pathway and cell proliferation. | None |
| The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. | None |
| Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3 half to different genes: characterization of the set gene. | None |
| The proto-oncogene SET interacts with muscarinic receptors and attenuates receptor signaling. | None |
| Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. | None |
| Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. | None |
| SET nuclear oncogene associates with microcephalin/MCPH1 and regulates chromosome condensation. | None |
| Analysis of nucleo-cytoplasmic shuttling of the proto-oncogene SET/I2PP2A. | None |
| study found SET, a putative oncogene was significantly downregulated in a bisphenol A dose-dependent manner; from gene network analysis, SET is predicted to communicate with other genes including CYP17, which is involved in biosynthesis and metabolism of sex-hormones | None |